In glioma, the combination of both therapies increased cytotoxic CD8+/CD4+ and CD8+/FoxP3+ T cell ratios, indicative of an enhanced anti-tumour activity (70), leading to longer-term surviving animals. The gene discussed is CD8A; the disease is central nervous system cancer.